Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

133TiP - Neoadjuvant osimertinib followed by sequential definitive radiotherapy and/or surgery in stage III EGFR-mutant NSCLC: An open-label, single-arm, phase II study


31 Mar 2023


Poster Display session


Waleed Kian


Journal of Thoracic Oncology (2023) 18 (4S): S106-S115.


W. Kian1, N. Peled2, L. C Roisman2, E. Levison3, J. Dudnik4, E. Chernomordikov3, E. Dudnik5, S. Keren-Rosenberg6, S. Tsuriel6, V. Hannes6, D. Hershkovitz6, R. Lichtenberg4, I. Granot2, B. Krayim2, W. Shalata3, A. M Allen2, P. Blumenfeld7, K. Lavrenkov3

Author affiliations

  • 1 Beer Sheva/IL
  • 2 Shaare Zedek Medical Center, Jerusalem/IL
  • 3 Soroka University Medical Center, Beer Sheva/IL
  • 4 Ben-Gurion University of the Negev, Beer Sheva/IL
  • 5 Ben-Gurion University of the Negev, Petah Tikva/IL
  • 6 Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv/IL
  • 7 Hadassah University Hospital - Ein Kerem, Jerusalem/IL


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 133TiP


The treatment of unresectable, locally advanced stage III non-small cell lung cancer (NSCLC) is concurrent chemoradiation therapy (CRT), followed by consolidation durvalumab. This study aims to evaluate the benefit of neoadjuvant osimertinib as an alternative therapy to this approach with the aim of reducing the radiation field.

Trial design

This investigation was a nonrandomized, open-label, single-arm, phase II prospective, proof-of-concept study. Eligible patients were treatment-naïve, nonoperable, stage III EGFR-mutant NSCLC patients. Patients received 80 mg oral osimertinib daily for 12 weeks prior to definitive radiotherapy (RT) and/or surgery. The response was assessed at week 6 and week 12. For responders, sequential definitive RT and/or surgery were planned. Nonresponders were started on standard CRT. After RT ± surgery or CRT, patients were followed for two years without adjuvant therapy. The primary endpoint was the objective response rate (ORR), with September 20, 2022 set as the cut-off for data collection. Secondary endpoints were safety and the gross tumour volume (GTV), planned tumour volume (PTV) and the percentage of total lung volume exceeding 20 Gy (V20%) before vs. after osimertinib. Exploratory analyses included assessments of the presence of plasma circulating tumour-free DNA (cfDNA) before osimertinib treatment, at weeks 6 and 12, at the end of RT, and 6 weeks post-RT.

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.